Source comparison
Head-to-Head Profile Comparison
Primary mechanism GABAergic modulation BDNF upregulation Primary effect Anxiolytic Cognitive enhancement Onset of action Minutes Days to weeks Typical research dosage 300–900 mcg/day 200–1,000 mcg/day Administration route Intranasal Sedation risk None reported
This comparison does not assign a generated winner or score.
- Primary mechanism
- GABAergic modulation
- BDNF upregulation
- Primary effect
- Anxiolytic
- Cognitive enhancement
- Onset of action
- Minutes
- Days to weeks
- Typical research dosage
- 300–900 mcg/day
- 200–1,000 mcg/day
- Administration route
- Intranasal
- Sedation risk
- None reported
- Regulatory status (Russia)
- Approved for anxiety
- Approved for cognition/neuroprotection
- Both compounds are administered intranasally, which bypasses first-pass metabolism and allows direct transport along olfactory pathways to the brain. This delivery method is a key advantage shared by both peptides and explains their relatively high bioavailability compared to oral alternatives.